Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
2022 Interim Results Presentation
09 - December - 2022
Latest corporate presentation following publication of the interim results for 2022-23.
Stalicla Licensing Deal10 - October - 2022
Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla
Evgen InvestorMeet - Interim Results 2022-2309 - December - 2022
CEO Dr Huw Jones and CFO Richard Moulson provide an update following publication of the interim results for 2022-23.
|Current Stakeholder||Number of shares||Percentage holding|
|J. R. Kight||33,100,000||12.0%|
|Seneca Investment Managers||14,932,071||5.4%|
|Chelverton Asset Management||12,500,000||4.5%|
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.